Summary & Overview
CPT 90284: Subcutaneous Immunoglobulin Injection (SCIg/IgSC)
CPT code 90284 identifies subcutaneous immunoglobulin (SCIg/IgSC) injections, a method of delivering passive antibody therapy for immunodeficiency and certain immune-mediated conditions. The code matters nationally because subcutaneous administration enables home- or clinic-based delivery, offers an alternative to intravenous immunoglobulin, and affects utilization patterns, care settings, and payer coverage strategies. Key payers referenced in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of clinical context and service settings for 90284, an outline of common payer coverage footprints, and an overview of what to expect in benchmarking and policy discussions related to subcutaneous immunoglobulin therapy. The publication addresses reimbursement benchmarks, site-of-service implications, and clinical considerations that shape coding and billing for SCIg. Data not available in the input for specific charge ranges, utilization rates, ICD-10 pairings, and taxonomy mappings is noted as unavailable for those items.
Billing Code Overview
CPT code 90284 describes subcutaneous immunoglobulin (SCIg or IgSC) administration. Immunoglobulin is a complex protein produced by the body to provide passive immunity and protect against infections. This code applies to subcutaneous injection of immunoglobulin formulations used for replacement therapy or immunomodulation.
-
Service type: Subcutaneous immunoglobulin injection (SCIg/IgSC)
-
Typical site of service: Outpatient clinic, infusion center, or patient home when administered via subcutaneous route
Clinical & Coding Specifications
Clinical Context
A typical patient for 90284 is an adult or pediatric patient with primary or secondary humoral immunodeficiency (for example, common variable immunodeficiency or hypogammaglobulinemia) who receives subcutaneous immunoglobulin (SCIg/IgSC) for passive immunity. The clinical workflow begins with diagnosis and determination of immunoglobulin replacement as medically necessary. The patient is evaluated in an outpatient infusion clinic, allergy/immunology office, or home health setting. Prior to initiation, baseline laboratories (CBC, IgG level, renal function) are obtained and a weight-based dose plan is calculated. For clinic-administered 90284, nursing staff prepare the prescribed SCIg product, select subcutaneous sites, and perform aseptic technique. The patient is observed for local site reactions and systemic adverse events for a brief period after injection. Education is provided on self-administration technique and potential adverse reactions when transitioning to home therapy. Documentation includes indication, lot number, dose, administration route (subcutaneous), injection sites, patient tolerance, and any immediate adverse events.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier/standard reporting | Used when no special modifier applies to the service. |